EcoDrugPlus

Ribosomal Protein L10a

Ensembl ID : ENSLLEG00000002869
Gene Symbol: RPL10A
1 View Cross-references
369 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L11

Ensembl ID : ENSLLEG00000008072
Gene Symbol: RPL11
1 View Cross-references
287 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L14

Ensembl ID : ENSLLEG00000020315
Gene Symbol: RPL14
1 View Cross-references
308 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L18a

Ensembl ID : ENSLLEG00000022434
Gene Symbol: RPL18A
1 View Cross-references
373 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L23

Ensembl ID : ENSLLEG00000022630
Gene Symbol: RPL23
1 View Cross-references
233 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L27a

Ensembl ID : ENSLLEG00000025360
Gene Symbol: RPL27A
1 View Cross-references
520 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L3

Ensembl ID : ENSLLEG00000021252
Gene Symbol: RPL3
1 View Cross-references
335 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L30

Ensembl ID : ENSLLEG00000011364
Gene Symbol: RPL30
1 View Cross-references
343 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L31

Ensembl ID : ENSLLEG00000003035
Gene Symbol: RPL31
1 View Cross-references
419 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L32

Ensembl ID : ENSLLEG00000023612
Gene Symbol: RPL32
1 View Cross-references
236 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L34

Ensembl ID : ENSLLEG00000004358
Gene Symbol: RPL34
1 View Cross-references
365 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L35

Ensembl ID : ENSLLEG00000026232
Gene Symbol: RPL35
1 View Cross-references
276 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).